FTC urged to reinstate Opana ER pay-for-delay case against Impax
A settlement agreement between Endo Pharmaceuticals and Impax Laboratories violated the antitrust law, an attorney for the Federal Trade Commission argued Thursday, seeking to reinstate a complaint against generic drugmaker Impax...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content